Merck’s
Sep 28, 2017
Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval
Another flop for Alzeimer’s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer's symptoms in participants of the trail. The news had plunged the Wall Street into another wav...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
